469 related articles for article (PubMed ID: 29719173)
61. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
[TBL] [Abstract][Full Text] [Related]
62. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
63. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer.
Han X; Liu D; Zhou Y; Wang L; Hou H; Chen H; Zhang L; Chen W; Li X; Zhao L
Cell Biol Int; 2021 Jan; 45(1):227-237. PubMed ID: 33090550
[TBL] [Abstract][Full Text] [Related]
64. MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway.
Wang X; Zhao H; Wang P; Zhang J; Li N; Liu Y; Zhang F; Yu Y
Anticancer Drugs; 2022 Nov; 33(10):989-998. PubMed ID: 36206129
[TBL] [Abstract][Full Text] [Related]
65. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
66. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p.
Gao ZQ; Wang JF; Chen DH; Ma XS; Yang W; Zhe T; Dang XW
Biomed Pharmacother; 2018 Jan; 97():809-817. PubMed ID: 29112934
[TBL] [Abstract][Full Text] [Related]
67. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
Wu J; Zhang L; Wu S; Yi X; Liu Z
Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
[TBL] [Abstract][Full Text] [Related]
68. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
69. Downregulation of microRNA-143-5p is required for the promotion of odontoblasts differentiation of human dental pulp stem cells through the activation of the mitogen-activated protein kinases 14-dependent p38 mitogen-activated protein kinases signaling pathway.
Wang BL; Wang Z; Nan X; Zhang QC; Liu W
J Cell Physiol; 2019 Apr; 234(4):4840-4850. PubMed ID: 30362514
[TBL] [Abstract][Full Text] [Related]
70. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
71. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
Guo J; Pan H
Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
[TBL] [Abstract][Full Text] [Related]
72. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
73. MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy.
Xiao S; Li Y; Pan Q; Ye M; He S; Tian Q; Xue M
J Cell Biochem; 2019 Mar; 120(3):2940-2953. PubMed ID: 30537410
[TBL] [Abstract][Full Text] [Related]
74. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
[TBL] [Abstract][Full Text] [Related]
75. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
76. LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling.
Zhang D; Guo H; Feng W; Qiu H
Life Sci; 2019 Sep; 232():116648. PubMed ID: 31301414
[TBL] [Abstract][Full Text] [Related]
77. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9.
Wang J; Xue X; Hong H; Qin M; Zhou J; Sun Q; Liang H; Gao L
Oncotarget; 2017 Jan; 8(1):574-582. PubMed ID: 27880941
[TBL] [Abstract][Full Text] [Related]
78. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
79. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1.
Wang Y; Bao W; Liu Y; Wang S; Xu S; Li X; Li Y; Wu S
Cell Death Dis; 2018 May; 9(5):447. PubMed ID: 29670086
[TBL] [Abstract][Full Text] [Related]
80. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
